secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001193125-25-006124
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports $850M cash, outlines 2025 pipeline milestones for KT-621, KT-295, KT-474
--------------------------------------------------------------------------------

- Preliminary cash ~$850M as of Dec 31, 2024; runway into mid-2027.
- KT-621 Phase 1 healthy volunteer data expected Q2 2025; Phase 1b AD starts Q2 2025 with data Q4 2025.
- KT-295 (TYK2) IND/Phase 1 start Q2 2025; data expected late 2025.
- KT-474 (IRAK4) Phase 2b dose-ranging in HS and AD ongoing, completion expected 1H26 and mid-2026.
- Novel oral immunology program (first-in-class) to be disclosed 1H2025; clinical testing expected early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/0001193125-25-006124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-006124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer